ArticleJournal of health, population, and nutrition2025
Global, regional, and national burden of neuroblastoma and peripheral nervous system tumours in individuals aged over 60 from 1990 to 2021: a trend analysis of global burden of disease study.
Article in Journal of health, population, and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aging and Peripheral Nerve Injuries: Impaired Repair, Inflammaging Impact, and Regeneration Resistance.Biomedicines · 2026Review
- Cantharidin Suppresses Cell Viability and Induces Apoptosis of SK-N-SH and SH-SY5Y Cells.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeElderly individuals diagnosed with neuroblastoma and peripheral nervous system tumours often have a poor prognosis. However, there is currently a lack of comprehensive analysis on these conditions in older adults. This study aims to determine the global epidemiological trends of neuroblastoma and peripheral nervous system tumours (in individuals aged 60 and above).
methodsWe obtained cross-sectional data from the 2021 Global Burden of Disease, Injuries, and Risk Factors Study (GBD) ( https://vizhub.healthdata.org/gbd-results/ ). We assessed the burden of neuroblastoma and peripheral nervous system tumours in the elderly from 1990 to 2021 using indicators such as prevalence and incidence. These indicators were classified by global, national, and regional levels, further stratified by Socio-Demographic Index (SDI), age, and gender. The results are organized by SDI, age, and gender categories.
resultsFrom 1990 to 2021, the global age-standardised prevalence and incidence rates of neuroblastoma and peripheral nervous system tumours among the elderly increased from 0.06 (95% UI 0.05, 0.08) and 0.12 (95% UI 0.09, 0.15) per 100,000 to 0.11 (95% UI 0.09, 0.13) and 0.22 (95% UI 0.17, 0.26) per 100,000, respectively. Age-standardised mortality and DALY rates also rose. Central Europe had the highest age-standardised prevalence and incidence rates in 2021, while Eastern Europe had the highest DALY rate. East Asia reported the highest number of total cases and experienced the fastest growth, with significant increases in prevalence, incidence, mortality, and DALY rates. Gender disparities were evident, with elderly men showing higher rates than women, and greater EAPC values indicating a higher increase in disease burden over time. The highest age-specific rates were found in the 90-94 age group, while the 70-74 age group had the highest DALY burden.
conclusionThe continuous rise in the incidence of neuroblastoma and peripheral nervous system tumours among the elderly highlights a pressing the necessity for focused public health measures and improved treatment approaches. Addressing the regional, gender, and age-related disparities requires a comprehensive approach that integrates medical advancements, social support, and public health policies. Future research should explore potential risk factors and innovative therapies to mitigate this growing global health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.